Laura Brege
CIK 1365619 · EVP, Corporate Affairs · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.01M
Companies
11
Total Filings
116
Lifetime Open-Market Net
-$16.43M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EWTX | Director | — | $43.52 | — | $0 | 5 | 2026-06-17 |
| MIRM | Director | 15,703 | $100.65 | $1.58M | -$1.15M | 10 | 2026-06-17 |
| PCRX | Director | 30,120 | $25.02 | $753.6K | -$1.24M | 21 | 2026-06-12 |
| ACAD | Director | 23,202 | $29.21 | $677.7K | -$5.19M | 31 | 2026-06-01 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 0 | — | — | $0 | 7 | 2020-07-02 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Director | — | $15.50 | — | $0 | 7 | 2019-05-31 |
| ARATANA THERAPEUTICS, INC. (PETX) Delisted | Director | 13,500 | — | — | $0 | 5 | 2018-07-30 |
| DCTH | Director | 0 | $15.11 | $0 | $0 | 3 | 2014-07-09 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | EVP, Corporate Affairs | 45,574 | — | — | -$8.85M | 20 | 2011-10-17 |
| ANGIOTECH PHARMACEUTICALS INC (ANPI) Delisted | Director | — | — | — | $0 | 2 | 2009-12-14 |
| ANGIOTECH PHARMACEUTICALS INC (JRT) Delisted | Director | — | — | — | $0 | 1 | 2008-12-10 |
Recent Filings · Page 4 of 12
116 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-06 | MIRM | Grant (A) | — | $0 | EDGAR |
| 2021-06-24 | ACAD | Grant (A) | — | $0 | EDGAR |
| 2021-06-11 | PCRX | Grant (A) | +1,066 | $0 | EDGAR |
| 2021-06-08 | MIRM | Grant (A) | — | $0 | EDGAR |
| 2020-11-17 | PCRX | Mixed | — | -$623.6K | EDGAR |
| 2020-07-02 | PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Disp (D) | −20,475 | -$368.6K | EDGAR |
| 2020-06-25 | ACAD | Grant (A) | — | $0 | EDGAR |
| 2020-06-15 | PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Grant (A) | +7,281 | $0 | EDGAR |
| 2020-06-15 | MIRM | Grant (A) | — | $0 | EDGAR |
| 2020-06-11 | PCRX | Grant (A) | +1,260 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.